BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...the first-line setting.At the 2018 meeting of the American Society of Clinical Oncology, AstraZeneca plc (LSE:AZN...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

...the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK...
...aligned with Trump.  Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...a new indication for these technologies.On Monday, Grail announced collaborations with Amgen Inc. (NASDAQ:AMGN), AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Regulation

EMA provides update on data breach, highlighting data security risk for sector

...cybertheft of American research on vaccine development. And in November reports surfaced of AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Politics, Policy & Law

Biden signals new path for Warp Speed, names Kessler to replace Slaoui

...President Donald Trump. Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 15, 2021
Product Development

Phase I/II antibody levels support single shot for J&J COVID-19 vaccine: Data Byte

...of the viral vector vaccine from AstraZeneca plc (LSE:AZN...
BioCentury | Jan 13, 2021
Politics, Policy & Law

Woodcock to serve as acting FDA commissioner, Sharfstein a contender for top FDA job

...the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...part of the Pfizer Breakthrough Growth Initiative. Vedanta, which was founded by PureTech Health plc (LSE:PRTC...
BioCentury | Jan 12, 2021
Product Development

Slaoui updates on COVID-19 vaccines, warns about slow enrollment in adolescent trial

...The company is testing and expects to deploy a single-dose regimen. Slaoui expects AstraZeneca plc (LSE:AZN...
...IIb trial in mid-February of a vaccine it is developing in partnership with GlaxoSmithKline plc (LSE:GSK...
Items per page:
1 - 10 of 24387
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...the first-line setting.At the 2018 meeting of the American Society of Clinical Oncology, AstraZeneca plc (LSE:AZN...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

...the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK...
...aligned with Trump.  Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...a new indication for these technologies.On Monday, Grail announced collaborations with Amgen Inc. (NASDAQ:AMGN), AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Regulation

EMA provides update on data breach, highlighting data security risk for sector

...cybertheft of American research on vaccine development. And in November reports surfaced of AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc (LSE:AZN...
BioCentury | Jan 15, 2021
Politics, Policy & Law

Biden signals new path for Warp Speed, names Kessler to replace Slaoui

...President Donald Trump. Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 15, 2021
Product Development

Phase I/II antibody levels support single shot for J&J COVID-19 vaccine: Data Byte

...of the viral vector vaccine from AstraZeneca plc (LSE:AZN...
BioCentury | Jan 13, 2021
Politics, Policy & Law

Woodcock to serve as acting FDA commissioner, Sharfstein a contender for top FDA job

...the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...part of the Pfizer Breakthrough Growth Initiative. Vedanta, which was founded by PureTech Health plc (LSE:PRTC...
BioCentury | Jan 12, 2021
Product Development

Slaoui updates on COVID-19 vaccines, warns about slow enrollment in adolescent trial

...The company is testing and expects to deploy a single-dose regimen. Slaoui expects AstraZeneca plc (LSE:AZN...
...IIb trial in mid-February of a vaccine it is developing in partnership with GlaxoSmithKline plc (LSE:GSK...
Items per page:
1 - 10 of 24387